Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | AIP | O00170 | 1/20 | 0.41 |
| ▸ | SGTA | O43765 | 1/20 | 0.41 |
| ▸ | TOMM70 | O94826 | 1/20 | 0.41 |
| ▸ | STIP1 | P31948 | 1/20 | 0.41 |
| ▸ | PPP5C | P53041 | 1/20 | 0.41 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.41 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.41 |
| ▸ | FKBP8 | Q14318 | 1/20 | 0.41 |
| ▸ | TOMM34 | Q15785 | 1/20 | 0.41 |
| ▸ | DNAJC7 | Q99615 | 1/20 | 0.41 |
| ▸ | AIPL1 | Q9NZN9 | 1/20 | 0.41 |
| ▸ | STUB1 | Q9UNE7 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869753 | 0.81 | MAPT (0.52) | ALDH1A1AIPSGTATOMM70STIP1 | |
| SCHEMBL5956052 | 0.77 | L3MBTL1 (0.33) | ALDH1A1AIPSGTATOMM70STIP1 | |
| SCHEMBL3863957 | 0.75 | CYP3A4 (0.46) | ALDH1A1NPSR1LMNATP53MAPT | |
| SCHEMBL13871294 | 0.72 | SMN1; SMN2 (0.40) | ALDH1A1NPSR1LMNAMAPTHPGD | |
| SCHEMBL8289831 | 0.67 | ALDH1A1 (0.78) | ALDH1A1NPSR1LMNAMAPTHPGD | |
| SCHEMBL5453212 | 0.67 | GAA (0.77) | ALDH1A1NPSR1LMNAMAPTHPGD | |
| SCHEMBL5291980 | 0.66 | ILK (0.52) | ALDH1A1LMNATP53MAPTHPGD | |
| SCHEMBL8442268 | 0.65 | SMN1; SMN2 (0.39) | ALDH1A1NPSR1LMNAMAPTHPGD | |
| SCHEMBL3863859 | 0.64 | KDR (0.45) | ALDH1A1AIPSGTATOMM70STIP1 | |
| SCHEMBL14218016 | 0.64 | PTPN1 (0.50) | ALDH1A1NPSR1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781673-B1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1781673-A1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | AstraZeneca AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781674-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTION OF CANCER | AstraZeneca AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006018627-A1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018628-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTI ON OF CANCER | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1601673-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078758-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | ALDH1A1 672/4885AIP 2753/4885SGTA 2206/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | ALDH1A1 672/4885AIP 2753/4885SGTA 2206/4885 |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | DHFR, DPYD, TYMS | ALDH1A1 172/4885AIP 3035/4885SGTA 2735/4885 |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | SDHA, CYP11B2, NQO1 | ALDH1A1 293/4885AIP 3636/4885SGTA 2728/4885 |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | CYP11B2, HCCS, CYP11B1 | ALDH1A1 214/4885AIP 3247/4885SGTA 3678/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | ALDH1A1 214/4885AIP 3247/4885SGTA 3678/4885 |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | BRCA1, CYP1B1, CCNI | ALDH1A1 316/4885AIP 3386/4885SGTA 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.